Not Signed In -
Stomach Ulcers |
|
|
Clinical Trial: Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
This study is no longer recruiting patients.
|
Purpose
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Stomach Neoplasms Esophageal Neoplasms | Drug: G17DT Immunogen | Phase II |
MedlinePlus related topics: Esophageal Cancer; Stomach Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
- Clinical diagnosis with gastric or gastroesophageal cancer
- Karnofsky performance status score of at least 70
- Life expectancy of at least 3 months
Exclusion criteria:
- Prior treatment with chemotherapy or anticancer immunotherapy
- Bone marrow transplant within past year
- Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease
- Central nervous system metastases
- Immunodeficiency
- Hypercalcemia
More Information
Study ID Numbers: GC4
Record last reviewed: July 2002
Last Updated: October 13, 2004
Record first received: July 31, 2002
ClinicalTrials.gov Identifier: NCT00042510
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: July 2002
Last Updated: October 13, 2004
Record first received: July 31, 2002
ClinicalTrials.gov Identifier: NCT00042510
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- H. pylori and Peptic Ulcer (National Institute of Diabetes and Digestive and Kidney Diseases)
- Stomach Ulcers (HealthWorld)
email this page
print this page
bookmark this page
feedback on this page
